1,495 reports of this reaction
7.5% of all ALPELISIB reports
#1 most reported adverse reaction
HYPERGLYCAEMIA is the #1 most commonly reported adverse reaction for ALPELISIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,495 FDA adverse event reports linking ALPELISIB to HYPERGLYCAEMIA. This represents approximately 7.5% of all 20,016 adverse event reports for this drug.
Patients taking ALPELISIB who experience hyperglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERGLYCAEMIA is moderately reported among ALPELISIB users, representing a notable but not dominant share of adverse events.
In addition to hyperglycaemia, the following adverse reactions have been reported for ALPELISIB:
The following drugs have also been linked to hyperglycaemia in FDA adverse event reports:
HYPERGLYCAEMIA has been reported as an adverse event in 1,495 FDA reports for ALPELISIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERGLYCAEMIA accounts for approximately 7.5% of all adverse event reports for ALPELISIB, making it one of the most commonly reported side effect.
If you experience hyperglycaemia while taking ALPELISIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.